[Immunisation: leaps into the future. Viral hepatitis].
作者信息
Bayas J M, Vilella A
机构信息
Servei de Medicina Preventiva. UASP-IDIBAPS. Hospital Clínic. Universitat de Barcelona. España.
出版信息
Aten Primaria. 2002 Nov 15;30(8):514-20. doi: 10.1016/s0212-6567(02)79090-2.
Abstract
摘要
相似文献
1
[Immunisation: leaps into the future. Viral hepatitis].
Aten Primaria. 2002 Nov 15;30(8):514-20. doi: 10.1016/s0212-6567(02)79090-2.
2
[Active and passive prevention of viral hepatitis].
Internist (Berl). 1991 May;32(5):249-55.
3
[Clinical studies of viral hepatitis--epidemiology, immunology and prevention].
Nihon Naika Gakkai Zasshi. 1986 Feb;75(2):173-6.
4
Recent advances in DNA vaccine of hepatitis virus.
Hepatobiliary Pancreat Dis Int. 2002 May;1(2):228-31.
5
Viral hepatitis: epidemiology, treatment, prevention.
Ethiop Med J. 2008 Apr;46(2):193-200.
6
[Vaccines against viral hepatitis. Current research and prospects].
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna. 1981 Jan-Feb;33(1):13-6.
7
[Prevention of viral hepatitis].
Nihon Naika Gakkai Zasshi. 1990 Aug 10;79(8):1001-6.
8
Hepatitis vaccines.
Dig Dis. 1997 Jan-Apr;15(1-2):1-22. doi: 10.1159/000171585.
9
Viral hepatitis.
Am J Nurs. 1983 Apr;83(4):571-86.
10
Symposium on clinical aspects in hepatitis virus infection. 1. Hepatitis viruses update.
Intern Med. 2001 Feb;40(2):173-5.
本文引用的文献
1
Perspectives: towards a peptide-based vaccine against hepatitis C virus.
Mol Immunol. 2001 Dec;38(6):475-84. doi: 10.1016/s0161-5890(01)00083-9.
2
Reflections on Epstein-Barr virus: some recently resolved old uncertainties.
J Infect. 2001 Aug;43(2):111-5. doi: 10.1053/jinf.2001.0898.
3
Expression, purification, immunological characterization and application of Escherichia coli-derived hepatitis C virus E2 proteins.
Biotechnol Appl Biochem. 2001 Oct;34(2):109-19. doi: 10.1042/ba20010036.
4
Control of a community-wide outbreak of hepatitis A by mass vaccination with inactivated hepatitis A vaccine.
Eur J Clin Microbiol Infect Dis. 2001 Mar;20(3):185-7. doi: 10.1007/s100960100461.
5
[Molecular biology of hepatitis C virus: implications for the development of new therapies and prophylactic vaccine].
Med Clin (Barc). 2001 Feb 10;116(5):191-7. doi: 10.1016/s0025-7753(01)71766-6.
6
Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group.
N Engl J Med. 2001 Feb 1;344(5):319-26. doi: 10.1056/NEJM200102013440501.
7
Iatrogenic exposure to mercury after hepatitis B vaccination in preterm infants.
J Pediatr. 2000 May;136(5):679-81. doi: 10.1067/mpd.2000.105133.
8
From the Centers for Disease Control and Prevention. Alternate two-dose hepatitis B vaccination schedule for adolescents aged 11-15 years.
JAMA. 2000 Apr 26;283(16):2100. doi: 10.1001/jama.283.16.2100-jwr0426-4-1.
9
[Prevention of transmissible diseases. Work Group for Transmissible Diseases of the PAPPS].
Aten Primaria. 1999 Dec;24 Suppl 1:99-117.
10
Recommendations regarding the use of vaccines that contain thimerosal as a preservative.
MMWR Morb Mortal Wkly Rep. 1999 Nov 5;48(43):996-8.
Zotero 插件